Health-related quality of life in psoriatic arthritis patients in Spain

Reumatologia Clinica

Volumn 10, Issue 1, 2014, Pages 25-31

  Gratacós, Jordi ^a   Daudén, Esteban ^b   Gómez Reino, Juan ^c   Moreno, José Carlos ^d   Casado, Miguel Ángel ^e   Rodríguez Valverde, Vicente ^f  

^a HOSPITAL DE SABADELL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Biological therapies; EQ 5D; Infliximab; Psoriatic arthritis; Quality of life; SF 36

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SPAIN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84895071462     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2013.05.006     Document Type: Article

References (29)

1. Krueger G.G. Clinical features of psoriatic arthritis. Am J Manag Care 2002, 8:S160-S170.
2. Zachariae H., Zachariae R., Blomqvist K., Davidsson S., Molin L., Mørk C., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002, 82:108-113.
3. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64:14-17.
4. García A., Ferrandiz C., Vanaclocha F., Lizán L., Badia X., Sellers G. What characterizes the severity of psoriasis?. Dermatology 2007, 216:137-151.
5. Husted J.A., Gladman D.D., Farewell V.T., Cook R.J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:51-58.
6. EuroQol a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. EuroQol Group.
7. Husted J.A., Gladman D.D., Farewell V.T., Long J.A., Cook R. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511-517.
8. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263.
9. McHorney C.A., Ware J.E., Lu J.F., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
10. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
11. Finlay A.Y., Coles E.C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132:236-244.
12. Ciocon D., Horn E., Kimball A. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol 2008, 9:111-117.
13. Salaffi F., Carotti M., Gasparini S., Intorcia M., Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009, 7:25.
14. Ruderman E.M. Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care. Am J Manag Care 2002, 8:171-180.
15. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
16. Daltroy L.H., Larson M.G., Roberts N.W., Liang M.H. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990, 17:946-950.
17. Badía X., Montserrat S., Roset M., Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999, 8:303-310.
18. Badia X., Roset M., Monserrat S., Herdman M., Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999, 112(Suppl. 1):79-85.
19. Herdman M., Badia X., Berra S. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Primaria 2001, 6:425-429.
20. Alonso J., Prieto L., Antón J.M. La versión española del SF-36 HealthSurvey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 1995, 104:771-776.
21. Alonso J., Regidor E., Barrio G., Prieto L., Rodríguez C., de la Fuente L. Valores poblacionales de referencia de la versión española del cuestionario de la salud SF-36. Med Clin (Barc) 1998, 111:410-416.
22. Vilagut G., Valderas J.M., Ferrer M., Garín O., López-García E., Alonso J. Interpretación de los cuestionarios de salud SF-36 y SF-12 en España: componentes físico y mental. Med Clin (Barc) 2008, 130:726-735.
23. Ferrándiz C., Pujol R.M., García-Patos V., Bordas X., Smandía J.A. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002, 46:867-873.
24. Carrascosa J.M., Pujol R., Daudén E., Hernanz-Hermosa J.M., Bordas X., Smandia J.A., et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006, 20:840-845.
25. Ackermann C., Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008, 26:121-129.
26. Langham S., Langham J., Goertz H.P., Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol 2011, 11:32.
27. Adams R., Walsh C., Veale D., Bresnihan B., FitzGerald O., Barry M. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010, 28:477-487.
28. Brodszky V., Péntek M., Bálint P.V., Géher P., Hajdu O., Hodinka L., et al. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand J Rheumatol 2010, 39:303-309.
29. Wade A.G., Crawford G.M., Pumford N., Koscielny V., Maycock S., McConnachie A. Baseline characteristics and patient reported data of patients prescribed etanercept: web-based and telephone evaluation. BMC Med Res Methodol 2011, 11:91.